cardiometabolic health

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

R&D

From obesity to outcomes abstract visual

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Interview at BIO-Europe 2026 with Robert Jacks

BIO-Europe Spring 2026: In conversation with Robert Jacks

Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.

R&D

Best practices in cardiometabolic trial design: Planning and...

Cardiometabolic disease is not a single entity. It is a broad spectrum of disorders that share common drivers.

R&D

Magnifying glass over years including 2026

Looking ahead to 2026 in biopharma

A look forward to trends to come in 2026, including AI-driven drug development, advanced modalities, and cardiometabolic disease therapies.

News

A hand holding a blackboard with the chalk-written word POSSIBLE

Novo Nordisk Foundation gives $75m for R&D 'challenges'

The Novo Nordisk Foundation's latest round of R&D funding will go towards projects in biomanufacturing, cardiometabolic diseases, and AI.

News

Digital programme improves metabolic health in diabetes

A comprehensive digital approach to helping patients manage type 2 diabetes, combining continuous glucose monitoring (CGM) devices, wearables and a mobile app, has been sh